The tariff classification of Bosentan Tablets in dosage form, from India
Issued December 4, 2015 by U.S. Customs and Border Protection.
Tariff classification
HTS codes: 3004.90.9120
Headings: 3004
Product description
The subject product, Bosentan Tablets in 62.5 mg and 125 mg, is a medicinal preparation containing Bosentan, an endothelin receptor antagonist, as the active ingredient. It is indicated for the treatment of pulmonary arterial hypertension.
CBP rationale
The applicable subheading for Bosentan Tablets in dosage form will be 3004.90.9120, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Cardiovascular medicaments.
Full text
N270805 December 4, 2015 CLA-2-30:OT:RR:NC:2:238 CATEGORY: Classification TARIFF NO.: 3004.90.9120 Mr. Pradeep Shah Zydus Pharmaceuticals USA Inc. 73 Route 31 North Pennington, NJ 08534 RE: The tariff classification of Bosentan Tablets in dosage form, from India Dear Mr. Shah: In your letter dated November 12, 2015, you requested a tariff classification ruling. The subject product, Bosentan Tablets in 62.5 mg and 125 mg, is a medicinal preparation containing Bosentan, an endothelin receptor antagonist, as the active ingredient. It is indicated for the treatment of pulmonary arterial hypertension. The applicable subheading for Bosentan Tablets in dosage form will be 3004.90.9120, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Cardiovascular medicaments.” Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on World Wide Web at http://www.usitc.gov/tata/hts/. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Judy Lee at [email protected]. Sincerely, Gwenn Klein Kirschner Director National Commodity Specialist Division
More rulings on the same tariff codes
The tariff classification of Olmesartan Medoxomil Tablets and Spironolactone Tablets in dosage form, from India and China, respectively
The tariff classification of Lisinopril Tablets, in dosage form, from India
The tariff classification of Enalapril Maleate Tablets, imported in dosage form, from Slovenia
The tariff classification of Xarelto® tablets in dosage form from Germany
The tariff classification of Adempas tablets in dosage form from Germany
The tariff classification of Metoprolol Succinate Extended Release Tablets and Candesartan Cilexetil Tablets, imported in dosage form, from India
The tariff classification of Ramipril Tablets, imported in dosage form, from India
The tariff classification of Sildenafil Tablets, imported in dosage form, from India
The tariff classification of Amlodipine Besylate (CAS-111470-99-6) and Benazepril Hydrochloride (CAS-86541-74-4), imported in dosage form, from India
The tariff classification of Quinapril Tablets, imported in dosage form, from India
Searching CBP rulings the smart way
TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.
Book a demo →